RxDoctor Payments DataLook up a doctor →

Aaron Latowsky, MD

Urology · Litchfield Park, AZNPI 1205992609

Payments from drug & device makers

$60,311in general payments, 2019–2025

Across 311 payments — averaging $193.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caldera Medical, Inc$36K
  • Medtronic$8K
  • Boston Scientific$8K
  • Coloplast$2K
  • AbbVie$695
  • Urogen Pharma, Inc.$646
  • plus $5K from 44 others
$355in research payments, 2019–2025

Across 1 payment — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$355

What the payments were for

  • Consulting fees$41,36369%
  • Speaking & faculty fees$4,7508%
  • Food & beverage$14,06023%
  • Education$700%
  • Gifts$690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,311 in reported general payments places this provider in the 90th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$612,448
Medicare patients
1,025
Services billed
28,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron14$11,711
Estradiol113$6,919
Finasteride328$4,567
Trospium Chloride59$2,603
Tamsulosin Hcl130$2,155
Solifenacin Succinate25$2,094
Potassium Citrate ErPotassium Citrate16$1,796
Chlorthalidone14$273
Ciprofloxacin Hcl27$100
Sildenafil Citrate21$75
Metronidazole16$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$333$11,71114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 269 urology providers in Arizona.

Other urology in Litchfield Park

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →